ArticleACS omega2020
Systems Studies Uncover miR-146a as a Target in
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Epigenetic landscape of Leishmania-host interactions.Epigenomics · 2025Review
- Genome-Wide Identification of Novel miRNAs and Infection-Related Proteins inPathogens (Basel, Switzerland) · 2025Article
- Investigation of the Expression Levels of miR-155, miR-133a, and miR-146b in the Serum of Acute and Chronic Forms of Cutaneous Leishmaniasis.Acta parasitologica · 2025Article
- Non-coding RNAs as emerging players inFrontiers in cellular and infection microbiology · 2025Article
- MicroRNAs orchestrating host and vector-borne protozoan interactions: bridging immune modulation and cross-species communication.Frontiers in immunology · 2025Review
- Determination of key hub genes in Leishmaniasis as potential factors in diagnosis and treatment based on a bioinformatics study.Scientific reports · 2024Article
- Synthetic biology for combating leishmaniasis.Frontiers in microbiology · 2024Article
- Article
- Comparative microRNA profiling ofFrontiers in cellular and infection microbiology · 2023Article
- The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.Virulence · 2022Review
- Bidirectional cytokine-microRNA control: A novel immunoregulatory framework in leishmaniasis.PLoS pathogens · 2022Review
- MicroRNAs: master regulators in host-parasitic protist interactions.Open biology · 2022Review
- Mechanobiology of immune cells: Messengers, receivers and followers in leishmaniasis aiding synthetic devices.Current research in immunology · 2022Review
- Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach.Oncotarget · 2022Article
- Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC - A systematic review.Frontiers in oncology · 2022Review
- Mammalian host microRNA response to plasmodial infection: role as therapeutic target and potential biomarker.Parasitology research · 2021Review
- Highlighting the interplay of microRNAs fromParasitology · 2021Review
- Variants of MIRNA146A rs2910164 and MIRNA499 rs3746444 are associated with the development of cutaneous leishmaniasis caused by Leishmania guyanensis and with plasma chemokine IL-8.PLoS neglected tropical diseases · 2021Article
- Activity of Anti-Microbial Peptides (AMPs) againstBiomolecules · 2021Review
- Super enhancer-mediated transcription of miR146a-5p drives M2 polarization during Leishmania donovani infection.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis, the second most neglected tropical disease, has been reported to affect approximately 12 million people worldwide. The causative protozoan parasite
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.